Sign in

You're signed outSign in or to get full access.

AT

Airsculpt Technologies, Inc. (AIRS)·Q1 2025 Earnings Summary

Executive Summary

  • Revenue of $39.371M, down 17.3% YoY; Adjusted EBITDA of $3.755M (9.5% margin), with profitability strengthening sequentially vs Q4 on similar revenue as cost actions took hold .
  • Introduced FY 2025 guidance: revenues $160–$170M and Adjusted EBITDA $16–$18M; affirmed in Q2 2025, signaling confidence in sequential improvement despite consumer headwinds .
  • Operational KPIs showed resilience: revenue per case stable at $12,799; lead volumes improved as marketing was re-focused; same‑store revenue declined ~24% YoY, consistent with expectations from Q4 trends .
  • Catalysts: rollout of expanded financing options by end of Q2, skin‑tightening pilot launch to capture GLP‑1‑driven demand; debt reduced by $10M post Q1 via equity raise, improving financial flexibility .
  • Liquidity remained tight but compliant with covenants: $5.6M cash at Q1, no revolver availability; management expects to remain covenant‑compliant through FY25 .

What Went Well and What Went Wrong

What Went Well

  • Cost discipline drove sequential EBITDA improvement: on essentially the same revenue base, Adjusted EBITDA was $1.9M higher vs Q4 2024 (“delivered $1.9 million more in adjusted EBITDA versus Q4 2024”) .
  • Go‑to‑market re-focus is working: “re‑focus of our marketing activities lifting lead volumes and improving our revenue decline as we exited the quarter” (CEO) .
  • Pricing power intact: average revenue per case remained consistent at $12,799; same‑center revenue per case grew 0.5% YoY, validating the premium positioning .

What Went Wrong

  • Volume pressure: cases fell 17.9% YoY to 3,076; same‑store revenue down ~24% YoY, reflecting softer consumer demand and prior marketing pullback .
  • Margin compression vs prior year: Adjusted EBITDA margin declined to 9.5% from 15.4% in Q1 2024; cost of service rose to 40.5% of revenue given fixed costs (rent, nursing) not flexing with sales .
  • Customer acquisition cost (CAC) elevated year‑over‑year ($3,130 vs $2,990) on lower case volumes despite $1.2M less advertising spend; conversion cycle elongated from ~45 to ~60 days .

Financial Results

Trend vs Prior Periods

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Millions)$42.548 $39.178 $39.371
Net (Loss)/Income ($USD Millions)$(6.040) $(5.034) $(2.847)
Diluted EPS ($)$(0.10) $(0.09) $(0.05)
Adjusted EBITDA ($USD Millions)$4.666 $1.855 $3.755
Adjusted EBITDA Margin (%)11.0% 4.7% 9.5%
Cases (units)3,277 3,064 3,076
Revenue per Case ($)$12,984 $12,787 $12,799

KPIs and Same‑Center Metrics

KPIQ3 2024Q4 2024Q1 2025
Same‑Center Cases (units)3,147 2,879 2,837
Same‑Center Case Growth (%)(8.1)% (21.8)% (24.3)%
Same‑Center Revenue per Case ($)$12,949 $12,797 $12,777
Facilities (period end)31 32 32
Procedure Rooms (period end)65 67 67
CAC ($ per case)—$3,250 $3,130
Cash & Equivalents ($USD Millions)$5.972 $8.235 $5.553
Gross Debt Outstanding ($USD Millions)—$75.8 (includes revolver draw) $74.7

Q1 2025 vs S&P Global Consensus

MetricActualConsensusSurprise
Revenue ($USD Millions)$39.371 $39.251*+$0.120M
Primary EPS ($)$(0.02)*$(0.033)*+$0.013
EBITDA ($USD Millions)$1.653*$2.943*$(1.290)M

Note: Values retrieved from S&P Global.*

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenues ($USD Millions)FY 2025—$160–$170Initiated
Adjusted EBITDA ($USD Millions)FY 2025—$16–$18Initiated
Revenues ($USD Millions)FY 2025 (as of Q2)$160–$170$160–$170Maintained
Adjusted EBITDA ($USD Millions)FY 2025 (as of Q2)$16–$18$16–$18Maintained

Management reiterated no de novo openings in 2025 embedded in guidance; expects covenant compliance throughout FY25 .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024)Previous Mentions (Q4 2024)Current Period (Q1 2025)Trend
Marketing reallocationEmphasis on paid search/social; lead growth; returns‑based approach introduced Cut marketing in H2’24 pressured leads; plan to increase and optimize Re‑focus lifted lead volumes; significant YoY lead growth without higher spend Improving
Sales conversion/processConsultative sales model enhancements; training; virtual consults Longer conversion cycle (~60 days) vs historical ~45 days Expanded training/process; conversion still elongated; expect improvements Stabilizing, gradual improvement
Financing options50% financing in Q4; expand lender base Plan to add new payment options Expanded financing rolling out by end of Q2; 44% financing in Q1 Near‑term catalyst
New services (skin tightening)Add‑on service in all centers; pilot standalone planned Pilot contemplated for Q2 Pilot launched in Q2; no FY25 guidance contribution assumed Early stage
Macro/tariffsConsumer pressure across aesthetics Soft consumer backdrop; elongated conversion Discretionary demand sensitive; monitor inflation/tariffs; service model not directly exposed to tariffs Headwind persists
Balance sheet/leverageCash $6.0M, liabilities rising Revolver draw; leverage 3.0x; covenant relief Cash $5.6M; leverage 3.76x; subsequent $13.8M equity raise and $10M debt prepayment (June) Improved post‑Q1

Management Commentary

  • “Profitability strengthen[ed] compared to the fourth quarter on similar revenue, reflecting our cost reduction initiatives and expense discipline” (CEO) .
  • “We generated strong lead volume growth… driving significant lead growth without increasing spend versus Q1 last year” (CEO) .
  • “Our guidance reflects current economic conditions… As we get back to… 2022–2023 same‑store revenue, we… approach long‑term ~30% EBITDA margins” (CEO) .
  • “Cost of service… increased to 40.5% [of revenue]… due to fixed cost components… As revenue trends improve, we expect this metric to align more closely with historical levels” (CFO) .
  • “Our leverage ratio was 3.76x… we intend to use excess cash and potential proceeds from any capital raise [to reduce leverage]” (CFO) .

Q&A Highlights

  • Cost savings durability: ~$3M annualized workforce reductions; benefits expected through 2025 .
  • Margin trajectory: FY25 EBITDA margin guide “just over 10%” appropriate; long‑term ~30% possible with return to 2022–2023 same‑store levels .
  • Demand/conversion: sequential momentum into March/April; goal to return to same‑store case growth exiting 2025; conversion cycle remains elongated .
  • Financing rollout: broadening by end of Q2; expected to aid conversion at $12–13K average ticket; initial Q1 financing usage 44% vs 50% in Q4 .
  • Skin‑tightening pilot: no contribution assumed in FY25 guide; incremental opportunity tied to GLP‑1‑driven skin laxity demand .

Estimates Context

  • Q1 2025 results slightly beat revenue consensus ($39.371M vs $39.251M*) and beat EPS consensus (Primary EPS $(0.02)* vs $(0.033)), reflecting stable pricing and cost controls offsetting volume pressure. Adjusted EBITDA outperformed sequentially but S&P EBITDA “actual” trails consensus ($1.653M vs $2.943M*), implying non‑GAAP adjustments drove investor focus .
  • FY25 guide suggests low‑teens EBITDA margin near‑term; estimate revisions may modestly improve on sequential trend, financing rollout, and pilot momentum, while same‑store volumes remain the key swing factor.
    Note: Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Sequential profitability improvement on flat revenue shows cost actions are working; watch Adjusted EBITDA progression into seasonally stronger Q2/Q3 .
  • Lead generation inflecting without higher spend; conversion and time‑to‑book remain bottlenecks—financing rollout is the near‑term catalyst to narrow that gap .
  • Volume recovery is prerequisite for margin normalization; fixed center costs (rent, nursing) will delever until same‑store cases turn positive .
  • Guidance credibility strengthened by Q2 affirmation and post‑Q1 capital actions (equity raise, $10M debt prepay), easing balance sheet risk and restoring revolver capacity .
  • New services (standalone skin tightening) can expand TAM and utilization of existing infrastructure; monitor pilot adoption and any FY25 contribution updates .
  • Macro sensitivity persists in discretionary aesthetics; management’s conservatism in guidance and focus on ROAS‑driven marketing are appropriate; upside if consumer stabilizes .
  • Medium‑term thesis: return to 2022–2023 same‑store levels could unlock ~30% EBITDA margins; execution on sales, financing, and marketing efficiency is the pathway per management .